ADHERENCE AND PERSISTENCE IN PATIENTS INITIATING TREATMENT WITH INJECTABLE THERAPIES FOR TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN

被引：1
|
作者：
Sicras-Mainar, A. [1 ]
Navarro, R. [2 ]
Ruiz, L. [3 ]
Morano, R. [3 ]
机构：
[1] Badalona Serv Assistencials, Barcelona, Spain
[2] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[3] GlaxoSmithKline, Madrid, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2122
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB82
引用
收藏
页码：A612 / A612
页数：1
相关论文
共 50 条
  • [1] Treatment Persistence and Switch in German Patients with Type 2 Diabetes Mellitus (T2DM) after Initiating Basal Insulin
    Chou, Engels
    Dippel, Franz-Werner
    Chung, Hsing-Wen
    [J]. DIABETES, 2014, 63 : A403 - A403
  • [2] Characteristics of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Therapy with Canagliflozin
    Martin, Silas C.
    Henk, Henry J.
    Chow, Wing
    [J]. DIABETES, 2014, 63 : A307 - A307
  • [3] HOW DIFFERENT WERE THEY? A TREATMENT PATTERN ANALYSIS OF UNITED STATES PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING INJECTABLE THERAPY
    Walker, V
    Wei, W.
    Thayer, S.
    Brekke, L.
    Crown, W.
    Grabner, M.
    Raparla, S.
    Quimbo, R.
    Cziraky, M.
    Hu, W.
    Cuddihy, R.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A493 - A493
  • [4] PATTERNS OF TREATMENT ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING LINAGLIPTIN AND OTHER NON-INSULIN DIABETES MEDICATIONS (NIDMS)
    Patorno, E.
    Gopalakrishnan, C.
    Zorina, O.
    Schneeweiss, S.
    Bartels, D.
    Seeger, J. D.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A57 - A57
  • [5] Characteristics and Medication Adherence of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Linagliptin and Other Diabetes Medications (Noninsulin) in Routine Care
    Patorno, Elisabetta
    Gopalakrishnan, Chandrasekar
    Zorina, Olesya
    Schneeweiss, Sebastian
    Bartels, Dorothee
    Liu, Jun
    Seeger, John
    [J]. DIABETES, 2015, 64 : A443 - A443
  • [6] ADHERENCE TO INJECTABLE ANTIDIABETIC THERAPIES (IAT) AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CHINA: RESULTS FROM A CROSS-SECTIONAL SURVEY STUDY
    Chen, T.
    Zhou, L.
    Ma, X.
    Wu, H.
    Cai, B.
    Tong, J.
    Liu, X.
    Ji, Q.
    [J]. VALUE IN HEALTH, 2020, 23 : S13 - S13
  • [7] Association of Treatment Persistence and Adherence With Real-World Outcomes Among Insulin-Treated Patients With Type 2 Diabetes Mellitus (T2DM)
    Wei, Wenhui
    Pan, Chunshen
    Xie, Lin
    Baser, Onur
    [J]. DIABETES, 2012, 61 : A4 - A4
  • [8] PATIENT PREFERENCES FOR ATTRIBUTES OF TYPE 2 DIABETES MELLITUS (T2DM) TREATMENTS IN SPAIN
    Mansfield, C. A.
    Sikirica, M.
    Pugh, A.
    Poulos, C.
    Martin, A. A.
    Ruiz Moran, L.
    Morano Larragueta, R.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A614 - A614
  • [9] Real-World Effectiveness, Adherence, and Persistence among Patients with T2DM Initiating Dulaglutide
    Mody, Reema
    Grabner, Michael
    Yu, Maria
    Turner, Ralph
    Kwan, Anita
    York, Whitney
    Lando, Laura Fernandez
    [J]. DIABETES, 2017, 66 : A355 - A355
  • [10] CLINICAL EXPERIENCES OF TYPE 2 DIABETES (T2DM) PATIENTS INITIATING ORAL SEMAGLUTIDE
    Dunn, T. J.
    Swift, C.
    Guesnier, A.
    Noone, J.
    Willey, V
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S309 - S309
12345